Related references
Note: Only part of the references are listed.Pharmacokinetic characterization in xenografted mice of a series of first-generation mimics for HLA-DR antibody, Lym-1, as carrier molecules to image and treat lymphoma
Gerald L. DeNardo et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
Novel radiolabeled antibody conjugates
D. M. Goldenberg et al.
ONCOGENE (2007)
Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: Optimal pharmacokinetics for therapy
Vania Kenanova et al.
CANCER RESEARCH (2007)
Successful radiotherapy of tumor in pretargeted mice by 188Re-radiolabeled phosphorodiamidate morpholino oligomer, a synthetic DNA analogue
Guozheng Liu et al.
CLINICAL CANCER RESEARCH (2006)
Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases:: Modern USA experience
Andrew S. Kennedy et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver:: Response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging
RJ Lewandowski et al.
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY (2005)
A novel platform for radioimmunotherapy:: Extracorporeal depletion of biotinylated and 90Y-labeled rituximab in patients with refractory B-cell lymphoma
O Lindén et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2005)
Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer
JF Kukowska-Latallo et al.
CANCER RESEARCH (2005)
Tumour therapy with radionuclides: assessment of progress and problems
J Carlsson et al.
RADIOTHERAPY AND ONCOLOGY (2003)
The two types of correction of absorbed dose estimates for internal emitters
LE Williams et al.
CANCER (2002)
Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin™ radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
GA Wiseman et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2001)
Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma: Preliminary report
KF Koral et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2000)
Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas
JM Vose et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
